Hakura Atsushi, Awogi Takumi, Shiragiku Toshiyuki, Ohigashi Atsushi, Yamamoto Mika, Kanasaki Kayoko, Oka Hiroaki, Dewa Yasuaki, Ozawa Shunsuke, Sakamoto Kouji, Kato Tatsuya, Yamamura Eiji
Global Drug Safety, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki, 300-2635, Japan.
Manufacturing Process Development Department, Otsuka Pharmaceutical Co., Ltd., 224-18 Hiraishi-Ebisuno, Kawauchi-cho, Tokushima-shi, Tokushima, 771-0182, Japan.
Genes Environ. 2021 Sep 30;43(1):41. doi: 10.1186/s41021-021-00206-1.
Ames test is used worldwide for detecting the bacterial mutagenicity of chemicals. In silico analyses of bacterial mutagenicity have recently gained acceptance by regulatory agencies; however, current in silico models for prediction remain to be improved. The Japan Pharmaceutical Manufacturers Association (JPMA) organized a task force in 2017 in which eight Japanese pharmaceutical companies had participated. The purpose of this task force was to disclose a piece of pharmaceutical companies' proprietary Ames test data.
Ames test data for 99 chemicals of various chemical classes were collected for disclosure in this study. These chemicals are related to the manufacturing process of pharmaceutical drugs, including reagents, synthetic intermediates, and drug substances. The structure-activity (mutagenicity) relationships are discussed in relation to structural alerts for each chemical class. In addition, in silico analyses of these chemicals were conducted using a knowledge-based model of Derek Nexus (Derek) and a statistics-based model (GT1_BMUT module) of CASE Ultra. To calculate the effectiveness of these models, 89 chemicals for Derek and 54 chemicals for CASE Ultra were selected; major exclusions were the salt form of four chemicals that were tested both in the salt and free forms for both models, and 35 chemicals called "known" positives or negatives for CASE Ultra. For Derek, the sensitivity, specificity, and accuracy were 65% (15/23), 71% (47/66), and 70% (62/89), respectively. The sensitivity, specificity, and accuracy were 50% (6/12), 60% (25/42), and 57% (31/54) for CASE Ultra, respectively. The ratio of overall disagreement between the CASE Ultra "known" positives/negatives and the actual test results was 11% (4/35). In this study, 19 out of 28 mutagens (68%) were detected with TA100 and/or TA98, and 9 out of 28 mutagens (32%) were detected with either TA1535, TA1537, WP2uvrA, or their combination.
The Ames test data presented here will help avoid duplicated Ames testing in some cases, support duplicate testing in other cases, improve in silico models, and enhance our understanding of the mechanisms of mutagenesis.
艾姆斯试验在全球范围内用于检测化学物质的细菌致突变性。细菌致突变性的计算机模拟分析最近已获得监管机构的认可;然而,目前用于预测的计算机模拟模型仍有待改进。日本制药商协会(JPMA)于2017年组织了一个特别工作组,八家日本制药公司参与其中。该特别工作组的目的是披露制药公司的专有艾姆斯试验数据。
本研究收集了99种不同化学类别的化学物质的艾姆斯试验数据以供披露。这些化学物质与药物制造过程相关,包括试剂、合成中间体和原料药。针对每种化学类别,结合结构警示讨论了结构-活性(致突变性)关系。此外,使用基于知识的Derek Nexus(Derek)模型和CASE Ultra基于统计的模型(GT1_BMUT模块)对这些化学物质进行了计算机模拟分析。为计算这些模型的有效性,为Derek选择了89种化学物质,为CASE Ultra选择了54种化学物质;主要排除的是四种化学物质的盐形式,这两种模型均对其盐形式和游离形式进行了测试,以及CASE Ultra中35种被称为“已知”阳性或阴性的化学物质。对于Derek,敏感性、特异性和准确性分别为65%(15/23)、71%(47/66)和70%(62/89)。对于CASE Ultra,敏感性、特异性和准确性分别为50%(6/12)、60%(25/42)和57%(31/54)。CASE Ultra“已知”阳性/阴性与实际测试结果之间的总体不一致率为11%(4/35)。在本研究中,28种诱变剂中有19种(68%)通过TA100和/或TA98检测到,28种诱变剂中有9种(32%)通过TA1535、TA1537、WP2uvrA或它们的组合检测到。
此处呈现的艾姆斯试验数据将有助于在某些情况下避免重复进行艾姆斯试验,在其他情况下支持重复试验,改进计算机模拟模型,并增进我们对诱变机制的理解。